NCT00490516View on ClinicalTrials.gov

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Schizophrenia
Interventions
DRUG

ACP-104

200 mg, tablet, BID, 6 weeks

DRUG

ACP-104

100 mg, tablet, BID, 6 weeks

DRUG

Placebo

placebo, tablet BID, 6 weeks

Trial Locations (21)

19139

Philadelphia

21202

Baltimore

30308

Atlanta

34208

Bradenton

34741

Kissimmee

63118

St Louis

78754

Austin

90232

Culver City

90660

Pico Rivera

90723

Paramount

91107

Pasadena

91206

Glendale

91724

Covina

92056

Oceanside

92108

San Diego

92506

Riverside

92626

Costa Mesa

92647

Huntington Beach

92805

Anaheim

92845

Garden Grove

08046

Willingboro

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY